GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (FRA:6IRA) » Definitions » Total Receivables

IRLAB Therapeutics AB (FRA:6IRA) Total Receivables : €0.69 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is IRLAB Therapeutics AB Total Receivables?

IRLAB Therapeutics AB's Total Receivables for the quarter that ended in Dec. 2024 was €0.69 Mil.


IRLAB Therapeutics AB Total Receivables Historical Data

The historical data trend for IRLAB Therapeutics AB's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Total Receivables Chart

IRLAB Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.46 1.68 1.12 0.80 0.69

IRLAB Therapeutics AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.99 5.77 1.07 0.69

IRLAB Therapeutics AB Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


IRLAB Therapeutics AB Total Receivables Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


IRLAB Therapeutics AB Business Description

Traded in Other Exchanges
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines